BACKGROUND: Vitamin D deficiency is common in HIV-infected individuals. In adults, traditional and HIV-related factors play a role in vitamin D status, and deficiency appears to impair immune restoration and exacerbate HIV complications, like cardiovascular disease (CVD). This study sought to determine factors contributing to vitamin D status in HIV-infected youth and investigate the relationship with CVD risk, inflammation and immune restoration. METHODS: HIV-infected subjects (1-25 years old) were enrolled prospectively along with healthy controls that were group-matched by age, sex and race. HIV data were collected for the HIV-infected group, while traditional risk factors, including vitamin D intake, sun exposure, skin pigmentation, physical activity level and body mass index (BMI) were collected for both groups. Fasting lipids, plasma 25-hydroxyvitamin D (25[OH]D), and inflammation markers were measured. RESULTS: In total, 200 HIV-infected subjects and 50 controls were enrolled. HIV group had 53% male, 95% Black and a mean age of 17.2 ±4.6 years. There was no difference in 25(OH)D between groups; 77% of HIV+ and 74% of controls had 25(OH)D<20 ng/ml. Only Fitzpatrick skin type was independently associated with 25(OH)D. No HIV variables were associated with 25(OH)D, even when HIV sub-populations were examined. Inflammation, CVD risk factors and immune restoration were not independently associated with 25(OH)D. CONCLUSIONS: Vitamin D deficiency is common among HIV-infected youth. However, HIV factors, CVD risk, inflammation and immune restoration do not appear to have the same relationship with vitamin D as has been shown in adults. Supplementation trials are needed to determine if increasing 25(OH)D concentrations could better elucidate these relationships.
BACKGROUND:Vitamin Ddeficiency is common in HIV-infected individuals. In adults, traditional and HIV-related factors play a role in vitamin D status, and deficiency appears to impair immune restoration and exacerbate HIV complications, like cardiovascular disease (CVD). This study sought to determine factors contributing to vitamin D status in HIV-infected youth and investigate the relationship with CVD risk, inflammation and immune restoration. METHODS:HIV-infected subjects (1-25 years old) were enrolled prospectively along with healthy controls that were group-matched by age, sex and race. HIV data were collected for the HIV-infected group, while traditional risk factors, including vitamin D intake, sun exposure, skin pigmentation, physical activity level and body mass index (BMI) were collected for both groups. Fasting lipids, plasma 25-hydroxyvitamin D (25[OH]D), and inflammation markers were measured. RESULTS: In total, 200 HIV-infected subjects and 50 controls were enrolled. HIV group had 53% male, 95% Black and a mean age of 17.2 ±4.6 years. There was no difference in 25(OH)D between groups; 77% of HIV+ and 74% of controls had 25(OH)D<20 ng/ml. Only Fitzpatrick skin type was independently associated with 25(OH)D. No HIV variables were associated with 25(OH)D, even when HIV sub-populations were examined. Inflammation, CVD risk factors and immune restoration were not independently associated with 25(OH)D. CONCLUSIONS:Vitamin Ddeficiency is common among HIV-infected youth. However, HIV factors, CVD risk, inflammation and immune restoration do not appear to have the same relationship with vitamin D as has been shown in adults. Supplementation trials are needed to determine if increasing 25(OH)D concentrations could better elucidate these relationships.
Authors: Peter Bergman; Lilian Walter-Jallow; Kristina Broliden; Birgitta Agerberth; Johan Söderlund Journal: Curr HIV Res Date: 2007-07 Impact factor: 1.581
Authors: M Kyla Shea; Sarah L Booth; Joseph M Massaro; Paul F Jacques; Ralph B D'Agostino; Bess Dawson-Hughes; José M Ordovas; Christopher J O'Donnell; Sekar Kathiresan; John F Keaney; Ramachandran S Vasan; Emelia J Benjamin Journal: Am J Epidemiol Date: 2007-11-15 Impact factor: 4.897
Authors: Carolien J P Van Den Bout-Van Den Beukel; Lydia Fievez; Meta Michels; Fred C G J Sweep; Ad R M M Hermus; Marjolein E W Bosch; David M Burger; Bert Bravenboer; Peter P Koopmans; André J A M Van Der Ven Journal: AIDS Res Hum Retroviruses Date: 2008-11 Impact factor: 2.205
Authors: Daniel X Tishkoff; Karl A Nibbelink; Kristina H Holmberg; Loredana Dandu; Robert U Simpson Journal: Endocrinology Date: 2007-11-01 Impact factor: 4.736
Authors: Stephen M Arpadi; Donald McMahon; Elaine J Abrams; Marukh Bamji; Murli Purswani; Ellen S Engelson; Mary Horlick; Elizabeth Shane Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Thomas J Wang; Michael J Pencina; Sarah L Booth; Paul F Jacques; Erik Ingelsson; Katherine Lanier; Emelia J Benjamin; Ralph B D'Agostino; Myles Wolf; Ramachandran S Vasan Journal: Circulation Date: 2008-01-07 Impact factor: 29.690
Authors: Virginia A Stallings; Joan I Schall; Mary L Hediger; Babette S Zemel; Florin Tuluc; Kelly A Dougherty; Julia L Samuel; Richard M Rutstein Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: Thomas R Ziegler; Grace A McComsey; Jennifer K Frediani; Erin C Millson; Vin Tangpricha; Allison Ross Eckard Journal: AIDS Res Hum Retroviruses Date: 2014-07-16 Impact factor: 2.205
Authors: Kelly A Dougherty; Joan I Schall; Babette S Zemel; Florin Tuluc; Xiaoling Hou; Richard M Rutstein; Virginia A Stallings Journal: J Pediatric Infect Dis Soc Date: 2014-03-27 Impact factor: 3.164
Authors: Vin Tangpricha; Suzanne E Judd; Thomas R Ziegler; Li Hao; Jessica A Alvarez; Anne M Fitzpatrick; Grace A McComsey; Allison Ross Eckard Journal: AIDS Res Hum Retroviruses Date: 2014-05-28 Impact factor: 2.205
Authors: Allison Ross Eckard; Mary Ann OʼRiordan; Julia C Rosebush; Joshua H Ruff; Ann Chahroudi; Danielle Labbato; Julie E Daniels; Monika Uribe-Leitz; Vin Tangpricha; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2017-12-15 Impact factor: 3.731
Authors: Rene F Chun; Nancy Q Liu; T Lee; Joan I Schall; Michelle R Denburg; Richard M Rutstein; John S Adams; Babette S Zemel; Virginia A Stallings; Martin Hewison Journal: J Steroid Biochem Mol Biol Date: 2014-08-01 Impact factor: 4.292